A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta.
- DOI
- 10.1186/s13023-025-03707-2
- Published
- 2025 Aug 11
- Container
- Orphanet journal of rare diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13023-025-03707-2,
title = {A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta.},
author = {Keyzor I and Martins AM and Uçar SK and Yamakawa H and Chien YH and Arslan N and Niu DM and Tümer L and Baldock L and Shohet S and Giuliano JD},
year = {2025},
journal = {Orphanet journal of rare diseases},
doi = {10.1186/s13023-025-03707-2},
url = {https://doi.org/10.1186/s13023-025-03707-2}
}RIS
TY - JOUR TI - A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta. AU - Keyzor I AU - Martins AM AU - Uçar SK AU - Yamakawa H AU - Chien YH AU - Arslan N AU - Niu DM AU - Tümer L AU - Baldock L AU - Shohet S AU - Giuliano JD PY - 2025 JO - Orphanet journal of rare diseases DO - 10.1186/s13023-025-03707-2 UR - https://doi.org/10.1186/s13023-025-03707-2 ER -
APA
I, K., AM, M., SK, U., H, Y., YH, C., N, A., DM, N., L, T., L, B., S, S., & JD, G. (2025). A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta.. Orphanet journal of rare diseases. https://doi.org/10.1186/s13023-025-03707-2
Source records
- pubmed · retrieved 2026-09-27T10:30:24.178Z